Loading company…
Yokohama-based biopharmaceutical company developing monoclonal antibody therapies for oncology and autoimmune diseases.
MabGenesis Inc. was founded in 2019 in Yokohama-shi, Japan, and develops biopharmaceutical products, including monoclonal antibodies and biologics, for oncology and autoimmune diseases. Its customers include hospitals, research organizations and pharmaceutical companies, through licensing and direct sales. The company has completed 4 deals. In December 2024 it raised JPY 470 million from Axil Capital Partners, Long Black Partners, Miyazaki Taiyo Capital and existing investor Regional Economy Vitalization Corporation of Japan. Katsuhiro Shinjo is CEO and founder.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in